Mandisa Singata-Madliki to Lamivudine
This is a "connection" page, showing publications Mandisa Singata-Madliki has written about Lamivudine.
Connection Strength
0,358
-
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Sci Rep. 2021 02 04; 11(1):3173.
Score: 0,181
-
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding. Antimicrob Agents Chemother. 2017 02; 61(2).
Score: 0,137
-
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial. Lancet HIV. 2019 05; 6(5):e307-e314.
Score: 0,040